**6. Future perspectives**

The development of novel antimicrobial compounds is critical for averting multidrug-resistant bacterial strains. Clinical trials showed that a large number of antimicrobial peptides have clinical potential. While AMPs have antimicrobial activity, in many cases, their clinical use has not been yet fully confirmed. Because of improper trial study design or lack of enough efficacy, many of the AMPs in clinical trials failed to progress to market. Thus, more research into the interaction between antimicrobial peptides and the human host would help to assess the true potential of these compounds.

Indeed, many of the antimicrobial compounds in clinical trials have some sort of chemical modification to improve their drug ability. The sophisticated digital libraries and modeling software would be useful for further optimization of the development of these compounds. In the future, we must try seriously to reduce the resistance to novel antimicrobial compounds. While AMPs have shown a lower tendency for resistance, this is an inevitable phenomenon due to evolutionary consequences. In fact, following the development of diverse antimicrobial agents and their mechanisms of antimicrobial action will impact antimicrobial resistance. In conclusion, it seems that through detailed monitoring and analysis of new antimicrobial drugs, limiting the use of antimicrobials in nonessential cases, and coadministration with antibiotics, the risk of appearance resistant bacterial strains will decrease in the future.
